Showing results (1-10 of 37) with videos related to

Sort By:
Pageof 4
Nature Reviews. Drug Discovery|September 15, 2020
Targeting the epigenetic regulation of antitumour immunitySimon J Hogg, Paul A Beavis, Mark A Dawson, et al.
Obstetrics and Gynecology International|December 1, 2015
Resveratrol, Acetyl-Resveratrol, and Polydatin Exhibit Antigrowth Activity against 3D Cell Aggregates of the SKOV-3 and OVCAR-8 Ovarian Cancer Cell LinesSimon J Hogg, Kenny Chitcholtan, Wafaa Hassan, et al.
Haematologica|December 30, 2020
Whole genome CRISPR screening identifies TOP2B as a potential target for IMiD sensitization in multiple myelomaMatteo Costacurta, Stephin J Vervoort, Simon J Hogg, et al.
Plos One|April 30, 2025
Muscleblind-like proteins are novel modulators of the tumor-immune microenvironmentAustin M Gabel, Edie I Crosse, Andrea E Belleville, et al.
Bioorganic & Medicinal Chemistry Letters|August 27, 2016
Development of single and mixed isoform selectivity PI3Kδ inhibitors by targeting Asn836 of PI3KδMichelle S Miller, Simon J Mountford, Jo-Anne Pinson, et al.
Nature Communications|August 9, 2020
The natural function of the malaria parasite's chloroquine resistance transporterSarah H Shafik, Simon A Cobbold, Kawthar Barkat, et al.
Molecular Cancer Therapeutics|July 14, 2016
BET Inhibition Induces Apoptosis in Aggressive B-Cell Lymphoma via Epigenetic Regulation of BCL-2 Family MembersSimon J Hogg, Andrea Newbold, Stephin J Vervoort, et al.
Biorxiv : the Preprint Server for Biology|January 8, 2024
Covalent Targeting of Splicing in T CellsKevin A Scott, Hiroyuki Kojima, Nathalie Ropek, et al.
Clinical Epigenetics|July 28, 2022
Distinct modulation of IFNγ-induced transcription by BET bromodomain and catalytic P300/CBP inhibition in breast cancerSimon J Hogg, Olga Motorna, Conor J Kearney, et al.
Pageof 4